Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Other financing activities: 2013-2025

Historic Other financing activities for Fortress Biotech (FBIO) over the last 9 years, with Sep 2025 value amounting to -$2,000.

  • Fortress Biotech's Other financing activities was N/A to -$2,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$7,000, marking a year-over-year change of. This contributed to the annual value of -$1,000 for FY2024, which is N/A change from last year.
  • Latest data reveals that Fortress Biotech reported Other financing activities of -$2,000 as of Q3 2025, which was down 200.00% from $2,000 recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Other financing activities ranged from a high of $275,000 in Q4 2021 and a low of -$6,000 during Q3 2022.
  • Its 2-year average for Other financing activities is -$800, with a median of -$1,000 in 2025.
  • Examining YoY changes over the last 5 years, Fortress Biotech's Other financing activities showed a top increase of 250.00% in 2022 and a maximum decrease of 500.00% in 2022.
  • Fortress Biotech's Other financing activities (Quarterly) stood at $275,000 in 2021, then slumped by 35.64% to $177,000 in 2022, then slumped by 200.00% to -$6,000 in 2023, then reached -$2,000 in 2025.
  • Its Other financing activities was -$2,000 in Q3 2025, compared to $2,000 in Q2 2025 and -$1,000 in Q1 2025.